These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 4283231)
1. [Expediency of the use of uroplasmin in clinical practice]. Skipetrov VP; Potapkina N; Chernyshev V; Shuvalov V Vrach Delo; 1974 Jan; (1):48-50. PubMed ID: 4283231 [No Abstract] [Full Text] [Related]
2. [Functional state of the kidneys in experimental immune nephritis during the use of heparin, urokinase and uroplasmin]. Monastyrskiĭ VA; Ambarova LI Urol Nefrol (Mosk); 1977; (4):23-5. PubMed ID: 143102 [No Abstract] [Full Text] [Related]
4. [State of the thrombin-plasmin system in nephrotoxic nephritis treated with heparin, urokinase, and uroplasmin]. Monastyrskiĭ VA; Ambarova LI Arkh Patol; 1980; 42(1):17-22. PubMed ID: 6445726 [TBL] [Abstract][Full Text] [Related]
5. [Laboratory control of fibrinolytic therapy]. Vinazzer H Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):30-7. PubMed ID: 2427412 [TBL] [Abstract][Full Text] [Related]
6. [State of renal structure and function in nephrotoxic nephritis treated with uroplasmin]. Monastyrskiĭ VA; Ambarova LI; Beshleĭ VI; Stasiuk NS Arkh Patol; 1978; 40(5):26-31. PubMed ID: 150828 [TBL] [Abstract][Full Text] [Related]
7. Thrombolytic therapy: an introduction and review. Thiagarajan D J Kans Med Soc; 1980 Jun; 81(6):292-3. PubMed ID: 6995538 [No Abstract] [Full Text] [Related]
9. [Thrombolytic therapy using urokinase: its mechanism and clinical use (author's transl)]. Sakuragawa N; Takahashi K Rinsho Ketsueki; 1977 Jun; 18(6):726-31. PubMed ID: 916203 [No Abstract] [Full Text] [Related]
10. [When is fibrinolytic therapy indicated?]. Woitinas F Med Klin; 1980 Feb; 75(3):98-107. PubMed ID: 6990218 [No Abstract] [Full Text] [Related]
11. [Indications and results of urokinase in vascular occlusions]. Trübestein G Dtsch Med Wochenschr; 1976 Dec; 101(52):1919-20. PubMed ID: 1001218 [No Abstract] [Full Text] [Related]
12. [Experimental aspects of the therapeutic action of urokinase in thromboembolic states]. Danilenko MV; Stasiuk NS Biull Eksp Biol Med; 1981 Mar; 91(3):293-5. PubMed ID: 7018613 [No Abstract] [Full Text] [Related]
13. Clot-selective thrombolysis: the impact of tissue-type plasminogen activator (t-PA) in thromboembolic diseases. Bounameaux H Vasa; 1986; 15(2):115-8. PubMed ID: 3088866 [No Abstract] [Full Text] [Related]
14. [Comparative effects of ancrod, urokinase and heparin on intraglomerular coagulation induced by progressive Masugi nephritis (author's transl)]. Fujioka M Nihon Jinzo Gakkai Shi; 1980 Aug; 22(8):1113-24. PubMed ID: 7012408 [No Abstract] [Full Text] [Related]
15. Use of thrombolytic agents. Hansen MS; Clemmensen I N Engl J Med; 1980 Apr; 302(14):813. PubMed ID: 6444452 [No Abstract] [Full Text] [Related]
16. [Biological changes during the local administration of small doses of urokinase]. Michaud A; Aiach M; Fiessinger JN; Vayssairat M; Juillet Y Nouv Presse Med; 1978 Oct; 7(35):3151. PubMed ID: 152910 [No Abstract] [Full Text] [Related]
17. An assessment of regional versus systemic thrombolytic treatment of peripheral and coronary artery thrombosis. Marder VJ; Francis CW Prog Hemost Thromb; 1984; 7():325-56. PubMed ID: 6241729 [No Abstract] [Full Text] [Related]
18. [Indications and results of thrombolytic treatment with urokinase of very severe pulmonary embolism]. Brochier M; Raynaud R; Griguer P; Faucchier JP; Morand P Boll Soc Ital Cardiol; 1973; 18(7):693-6. PubMed ID: 4620067 [No Abstract] [Full Text] [Related]
19. Thrombolytic treatment of venous thromboembolism. Gurewich V Vasc Surg; 1977; 11(6):341-2. PubMed ID: 616147 [No Abstract] [Full Text] [Related]